Eli Lilly launches PhIII JAK study, aiming for the first drug to lower mortality in Covid-19
Soon after the NIH announced in late April that Eli Lilly’s JAK inhibitor baricitinib would be the second drug tested in the trial that had …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
